Attovia Therapeutics (ATTO) insider converts preferred to common and buys more shares
Rhea-AI Filing Summary
Frazier Life Sciences XI, L.P., together with affiliated general partners FHMLS XI, L.P. and FHMLS XI, L.L.C., reported multiple conversions of preferred stock in Attovia Therapeutics, Inc. On August 6, 2026, Series A‑1, A‑2, B and C Preferred Stock automatically converted into Common Stock on a 9.29:1 basis immediately upon closing of Attovia’s initial public offering, eliminating these preferred positions. In connection with these automatic conversions, Frazier received blocks of Attovia Common Stock, all held directly by Frazier Life Sciences XI, L.P. In a separate transaction the same day, Frazier purchased 588,235 shares of Attovia Common Stock at $17.00 per share in an open‑market or private transaction, increasing its Common Stock holdings; post‑transaction Common Stock balances are not specified in this report.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 6,078,864 shares
Net Buy
9 txns
Insider
Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C.
Role
10% Owner | 10% Owner | 10% Owner
Bought
588,235 shs ($10.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A-1 Preferred Stock F1, F2 | 16,250,000 | $0.00 | $0.00 |
| Conversion | Series A-2 Preferred Stock F3, F2 | 14,772,727 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock F4, F2 | 11,054,544 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock F5, F2 | 8,930,685 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F2 | 1,749,192 | -- | -- |
| Conversion | Common Stock F3, F2 | 1,590,175 | -- | -- |
| Conversion | Common Stock F4, F2 | 1,189,940 | -- | -- |
| Conversion | Common Stock F5, F2 | 961,322 | -- | -- |
| Purchase | Common Stock F2 | 588,235 | $17.00 | $10.00M |
Holdings After Transaction:
Series A-1 Preferred Stock — 0 shares (Direct);
Series A-2 Preferred Stock — 0 shares (Direct);
Series B Preferred Stock — 0 shares (Direct);
Series C Preferred Stock — 0 shares (Direct);
Common Stock — 6,154,213 shares (Direct)
Footnotes (5)
- F1. The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
- F2. The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.
- F3. The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
- F4. The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
- F5. The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
Key Figures
Series A-1 Preferred Converted: 16,250,000 shares
Series A-1 Underlying Common: 1,749,192 shares
Series A-2 Preferred Converted: 14,772,727 shares
+5 more
8 metrics
Series A-1 Preferred Converted
16,250,000 shares
Series A-1 Preferred Stock automatically converted into Common Stock on a 9.29:1 basis at IPO closing
Series A-1 Underlying Common
1,749,192 shares
Common Stock received upon conversion of Series A-1 Preferred Stock on August 6, 2026
Series A-2 Preferred Converted
14,772,727 shares
Series A-2 Preferred Stock automatically converted into Common Stock on a 9.29:1 basis at IPO closing
Series A-2 Underlying Common
1,590,175 shares
Common Stock received upon conversion of Series A-2 Preferred Stock on August 6, 2026
Series B Preferred Converted
11,054,544 shares
Series B Preferred Stock automatically converted into Common Stock on a 9.29:1 basis at IPO closing
Series C Preferred Converted
8,930,685 shares
Series C Preferred Stock automatically converted into Common Stock on a 9.29:1 basis at IPO closing
Common Shares Purchased
588,235 shares
Code P purchase of Attovia Common Stock on August 6, 2026
Purchase Price
$17.00 per share
Price paid for 588,235 Attovia Common shares in open-market or private transaction
Key Terms
automatic conversion, initial public offering, preferred stock, 10% owner, +1 more
5 terms
automatic conversion financial
"Series A-1 Preferred Stock automatically converted into shares of Common Stock"
initial public offering financial
"automatically converted into shares of Common Stock immediately upon closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
preferred stock financial
"The Series B Preferred Stock automatically converted into shares of Common Stock"
Preferred stock is a type of ownership in a company that typically offers investors higher and more consistent dividend payments than common stock. Unlike regular shares, preferred stock usually doesn’t come with voting rights but provides a priority claim on the company’s assets and profits, making it a more stable and predictable investment option. This makes preferred stock attractive to those seeking steady income with lower risk.
10% owner financial
"Frazier Life Sciences XI, L.P. is marked as a ten percent owner"
derivative security financial
"transaction code C described as Conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider activity did Frazier Life Sciences report in ATTO on August 6, 2026?
Frazier Life Sciences reported automatic conversions of multiple Attovia preferred stock series into Common Stock upon the IPO closing, and a separate purchase of 588,235 Common shares at $17.00 per share on August 6, 2026.
Was Frazier’s Attovia (ATTO) trading under a Rule 10b5-1 plan?
The filing’s Rule 10b5‑1 checkbox is not marked as an affirming trading plan. There is no footnote stating that the reported Attovia transactions were executed pursuant to a pre‑arranged Rule 10b5‑1 trading plan.
Did Frazier Life Sciences retain any Attovia preferred stock after the IPO conversion?
No preferred stock is shown as remaining. Each series of Attovia preferred stock reports 0 shares following the automatic IPO-related conversion, indicating those preferred positions were fully converted into Common Stock on August 6, 2026.